Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

Sexually Transmitted Infections

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...

Leishmaniasis

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026

Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026

Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal·2026

Same author

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Cancers·2026

Same author

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Cancers·2026

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Update on HIV lymphoma.

¹Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10064, USA. noya@mskcc.org

Current Oncology Reports

|August 21, 2007

Summary

Despite antiretroviral therapy, HIV patients face higher malignancy risks, particularly lymphoma. Research shows Rituximab improves outcomes but may increase infections in some, highlighting ongoing treatment advancements.

Area of Science:

Oncology
Infectious Diseases
Immunology

Background:

Individuals with HIV infection in industrialized nations are at elevated risk for malignancies, even with highly active antiretroviral therapy (HAART).
Lymphoma is the most prevalent malignancy associated with HIV in these regions.
This review focuses on advancements in understanding and treating HIV-associated lymphomas between January 2005 and February 2007.

Purpose of the Study:

To review recent progress in the diagnosis and management of HIV-associated lymphomas.
To highlight key findings regarding diffuse large B cell lymphoma (DLBCL) and the role of Rituximab.
To summarize new biologic insights into various HIV-associated lymphomas and coinfections.

Main Methods:

Literature review of studies published from January 2005 to February 2007.

Related Experiment Videos

Last Updated: Jul 13, 2026

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Focus on research concerning diffuse large B cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma (HL) in HIV-infected individuals.

Analysis of data on treatment efficacy, side effects, and biologic insights.

Main Results:

Infusional therapy for DLBCL shows promise but presents logistical challenges.
Rituximab appears to enhance complete response rates and potentially overall survival in HIV-associated lymphomas.
A subset of patients with very low CD4 counts may experience increased infections when treated with Rituximab.
Progress has been made in understanding the biology of HIV-associated NHL, HL, and associated virologic coinfections.

Conclusions:

Treatment outcomes for HIV-associated lymphomas, including NHL and HL, are progressively improving.
Continued research into pathophysiology and novel therapeutic strategies is crucial for further advancements.
Balancing treatment efficacy with potential side effects, such as infections, remains a key consideration.